The global Bio Similars & Subsequent Entry Biologic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bio Similars & Subsequent Entry Biologic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bio Similars & Subsequent Entry Biologic.
Report Scope
The Bio Similars & Subsequent Entry Biologic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bio Similars & Subsequent Entry Biologic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bio Similars & Subsequent Entry Biologic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bio Similars & Subsequent Entry Biologic companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bio Similars & Subsequent Entry Biologic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Market by Application
1.3.1 Global Bio Similars & Subsequent Entry Biologic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bio Similars & Subsequent Entry Biologic Market Perspective (2019-2030)
2.2 Bio Similars & Subsequent Entry Biologic Growth Trends by Region
2.2.1 Global Bio Similars & Subsequent Entry Biologic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bio Similars & Subsequent Entry Biologic Historic Market Size by Region (2019-2024)
2.2.3 Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Region (2025-2030)
2.3 Bio Similars & Subsequent Entry Biologic Market Dynamics
2.3.1 Bio Similars & Subsequent Entry Biologic Industry Trends
2.3.2 Bio Similars & Subsequent Entry Biologic Market Drivers
2.3.3 Bio Similars & Subsequent Entry Biologic Market Challenges
2.3.4 Bio Similars & Subsequent Entry Biologic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bio Similars & Subsequent Entry Biologic Players by Revenue
3.1.1 Global Top Bio Similars & Subsequent Entry Biologic Players by Revenue (2019-2024)
3.1.2 Global Bio Similars & Subsequent Entry Biologic Revenue Market Share by Players (2019-2024)
3.2 Global Bio Similars & Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bio Similars & Subsequent Entry Biologic Revenue
3.4 Global Bio Similars & Subsequent Entry Biologic Market Concentration Ratio
3.4.1 Global Bio Similars & Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bio Similars & Subsequent Entry Biologic Revenue in 2023
3.5 Bio Similars & Subsequent Entry Biologic Key Players Head office and Area Served
3.6 Key Players Bio Similars & Subsequent Entry Biologic Product Solution and Service
3.7 Date of Enter into Bio Similars & Subsequent Entry Biologic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bio Similars & Subsequent Entry Biologic Breakdown Data by Type
4.1 Global Bio Similars & Subsequent Entry Biologic Historic Market Size by Type (2019-2024)
4.2 Global Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Type (2025-2030)
5 Bio Similars & Subsequent Entry Biologic Breakdown Data by Application
5.1 Global Bio Similars & Subsequent Entry Biologic Historic Market Size by Application (2019-2024)
5.2 Global Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
6.2 North America Bio Similars & Subsequent Entry Biologic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
6.4 North America Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
7.2 Europe Bio Similars & Subsequent Entry Biologic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
7.4 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
8.2 Asia-Pacific Bio Similars & Subsequent Entry Biologic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bio Similars & Subsequent Entry Biologic Market Size by Region (2019-2024)
8.4 Asia-Pacific Bio Similars & Subsequent Entry Biologic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
9.2 Latin America Bio Similars & Subsequent Entry Biologic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
9.4 Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
10.2 Middle East & Africa Bio Similars & Subsequent Entry Biologic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
10.4 Middle East & Africa Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sun Pharma
11.1.1 Sun Pharma Company Detail
11.1.2 Sun Pharma Business Overview
11.1.3 Sun Pharma Bio Similars & Subsequent Entry Biologic Introduction
11.1.4 Sun Pharma Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.1.5 Sun Pharma Recent Development
11.2 Synthon Pharmaceuticals
11.2.1 Synthon Pharmaceuticals Company Detail
11.2.2 Synthon Pharmaceuticals Business Overview
11.2.3 Synthon Pharmaceuticals Bio Similars & Subsequent Entry Biologic Introduction
11.2.4 Synthon Pharmaceuticals Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.2.5 Synthon Pharmaceuticals Recent Development
11.3 Teva Pharmaceutical Industries
11.3.1 Teva Pharmaceutical Industries Company Detail
11.3.2 Teva Pharmaceutical Industries Business Overview
11.3.3 Teva Pharmaceutical Industries Bio Similars & Subsequent Entry Biologic Introduction
11.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.3.5 Teva Pharmaceutical Industries Recent Development
11.4 LG Life Sciences
11.4.1 LG Life Sciences Company Detail
11.4.2 LG Life Sciences Business Overview
11.4.3 LG Life Sciences Bio Similars & Subsequent Entry Biologic Introduction
11.4.4 LG Life Sciences Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.4.5 LG Life Sciences Recent Development
11.5 Celltrion Biocon
11.5.1 Celltrion Biocon Company Detail
11.5.2 Celltrion Biocon Business Overview
11.5.3 Celltrion Biocon Bio Similars & Subsequent Entry Biologic Introduction
11.5.4 Celltrion Biocon Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.5.5 Celltrion Biocon Recent Development
11.6 Hospira
11.6.1 Hospira Company Detail
11.6.2 Hospira Business Overview
11.6.3 Hospira Bio Similars & Subsequent Entry Biologic Introduction
11.6.4 Hospira Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.6.5 Hospira Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Bio Similars & Subsequent Entry Biologic Introduction
11.7.4 Merck Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Biogen idec
11.8.1 Biogen idec Company Detail
11.8.2 Biogen idec Business Overview
11.8.3 Biogen idec Bio Similars & Subsequent Entry Biologic Introduction
11.8.4 Biogen idec Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.8.5 Biogen idec Recent Development
11.9 Genentech (Roche)
11.9.1 Genentech (Roche) Company Detail
11.9.2 Genentech (Roche) Business Overview
11.9.3 Genentech (Roche) Bio Similars & Subsequent Entry Biologic Introduction
11.9.4 Genentech (Roche) Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.9.5 Genentech (Roche) Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Bio Similars & Subsequent Entry Biologic Introduction
11.10.4 Pfizer Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.10.5 Pfizer Recent Development
11.11 Celltrion
11.11.1 Celltrion Company Detail
11.11.2 Celltrion Business Overview
11.11.3 Celltrion Bio Similars & Subsequent Entry Biologic Introduction
11.11.4 Celltrion Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.11.5 Celltrion Recent Development
11.12 Biocon
11.12.1 Biocon Company Detail
11.12.2 Biocon Business Overview
11.12.3 Biocon Bio Similars & Subsequent Entry Biologic Introduction
11.12.4 Biocon Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.12.5 Biocon Recent Development
11.13 Amgen
11.13.1 Amgen Company Detail
11.13.2 Amgen Business Overview
11.13.3 Amgen Bio Similars & Subsequent Entry Biologic Introduction
11.13.4 Amgen Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.13.5 Amgen Recent Development
11.14 Samsung Biologics
11.14.1 Samsung Biologics Company Detail
11.14.2 Samsung Biologics Business Overview
11.14.3 Samsung Biologics Bio Similars & Subsequent Entry Biologic Introduction
11.14.4 Samsung Biologics Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.14.5 Samsung Biologics Recent Development
11.15 Mylan
11.15.1 Mylan Company Detail
11.15.2 Mylan Business Overview
11.15.3 Mylan Bio Similars & Subsequent Entry Biologic Introduction
11.15.4 Mylan Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.15.5 Mylan Recent Development
11.16 Dr. Reddy's Laboratories
11.16.1 Dr. Reddy's Laboratories Company Detail
11.16.2 Dr. Reddy's Laboratories Business Overview
11.16.3 Dr. Reddy's Laboratories Bio Similars & Subsequent Entry Biologic Introduction
11.16.4 Dr. Reddy's Laboratories Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.16.5 Dr. Reddy's Laboratories Recent Development
11.17 Stada Arzneimittel AG
11.17.1 Stada Arzneimittel AG Company Detail
11.17.2 Stada Arzneimittel AG Business Overview
11.17.3 Stada Arzneimittel AG Bio Similars & Subsequent Entry Biologic Introduction
11.17.4 Stada Arzneimittel AG Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.17.5 Stada Arzneimittel AG Recent Development
11.18 AbbVie
11.18.1 AbbVie Company Detail
11.18.2 AbbVie Business Overview
11.18.3 AbbVie Bio Similars & Subsequent Entry Biologic Introduction
11.18.4 AbbVie Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.18.5 AbbVie Recent Development
11.19 Sanofi-Aventis
11.19.1 Sanofi-Aventis Company Detail
11.19.2 Sanofi-Aventis Business Overview
11.19.3 Sanofi-Aventis Bio Similars & Subsequent Entry Biologic Introduction
11.19.4 Sanofi-Aventis Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.19.5 Sanofi-Aventis Recent Development
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Detail
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson Bio Similars & Subsequent Entry Biologic Introduction
11.20.4 Johnson & Johnson Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.20.5 Johnson & Johnson Recent Development
11.21 Novo Nordisk
11.21.1 Novo Nordisk Company Detail
11.21.2 Novo Nordisk Business Overview
11.21.3 Novo Nordisk Bio Similars & Subsequent Entry Biologic Introduction
11.21.4 Novo Nordisk Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.21.5 Novo Nordisk Recent Development
11.22 Eli Lilly
11.22.1 Eli Lilly Company Detail
11.22.2 Eli Lilly Business Overview
11.22.3 Eli Lilly Bio Similars & Subsequent Entry Biologic Introduction
11.22.4 Eli Lilly Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.22.5 Eli Lilly Recent Development
11.23 Novartis
11.23.1 Novartis Company Detail
11.23.2 Novartis Business Overview
11.23.3 Novartis Bio Similars & Subsequent Entry Biologic Introduction
11.23.4 Novartis Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.23.5 Novartis Recent Development
11.24 3sbio
11.24.1 3sbio Company Detail
11.24.2 3sbio Business Overview
11.24.3 3sbio Bio Similars & Subsequent Entry Biologic Introduction
11.24.4 3sbio Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.24.5 3sbio Recent Development
11.25 Biotech
11.25.1 Biotech Company Detail
11.25.2 Biotech Business Overview
11.25.3 Biotech Bio Similars & Subsequent Entry Biologic Introduction
11.25.4 Biotech Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.25.5 Biotech Recent Development
11.26 Gelgen
11.26.1 Gelgen Company Detail
11.26.2 Gelgen Business Overview
11.26.3 Gelgen Bio Similars & Subsequent Entry Biologic Introduction
11.26.4 Gelgen Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.26.5 Gelgen Recent Development
11.27 Innovent
11.27.1 Innovent Company Detail
11.27.2 Innovent Business Overview
11.27.3 Innovent Bio Similars & Subsequent Entry Biologic Introduction
11.27.4 Innovent Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.27.5 Innovent Recent Development
11.28 Dong Bao
11.28.1 Dong Bao Company Detail
11.28.2 Dong Bao Business Overview
11.28.3 Dong Bao Bio Similars & Subsequent Entry Biologic Introduction
11.28.4 Dong Bao Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.28.5 Dong Bao Recent Development
11.29 Ganlee
11.29.1 Ganlee Company Detail
11.29.2 Ganlee Business Overview
11.29.3 Ganlee Bio Similars & Subsequent Entry Biologic Introduction
11.29.4 Ganlee Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.29.5 Ganlee Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
听
听
*If Applicable.
